EMA Authorised: Qtern (saxagliptin;dapagliflozin propanediol monohydrate) — Astra Zeneca AB

View source ↗

Summary

The EMA has authorised Qtern (saxagliptin and dapagliflozin propanediol monohydrate) for treatment of type 2 diabetes and related metabolic conditions, with Ast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• QTERN (saxagliptin and dapagliflozin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2;Diabetes Mellitus;Nutritional and Metabolic Diseases;Metabolic Diseases;Glucose Metabolism Disorders. MAH: Astra Zeneca AB. Decision date: 12/03/2026